In a meta-analysis, when compared with docetaxel, ICI improved OS in patients with KRAS mutant NSCLC.[29] Other studies revealed a similar or better ICI treatment efficacy for NSCLC patients harboring KRAS mutations than those with KRAS wild type.[11,30–32] Different KRAS subtypes have been shown correlated to PD-L1 expression levels. This evidence concerns the gene KRAS and non-small cell lung carcinoma.